Halozyme Therapeutics has entered a global collaboration and license agreement with Eli Lilly and Co. to develop and commercialize products combining Lilly compounds with Halozyme’s ENHANZE platform.   Halozyme will receive $25 million upfront, along with milestone payments of as much as $160 million for each target, valued at as much as $800 million. Payments will be based on development, regulatory and sales-based milestones, as well as royalties on any products commercialized.   The...